| Cash Flow | 2025-06-30 |
|---|---|
| Stock-based compensation expense | 15,660 |
| Net loss | -111,866 |
| Amortization of discount on marketable securities | 1,423 |
| Prepaid expenses and other current assets | 1,389 |
| Other receivable | 8,105 |
| Other long-term assets | -1,072 |
| Accrued expenses and other liabilities | -15,526 |
| Collaboration receivable - related party | 7,136 |
| Accounts payable | -12,007 |
| Depreciation expense | 216 |
| Premium on marketable securities | 295 |
| Right-of-use operating asset | -796 |
| Operating lease liabilities, non-current | -975 |
| Operating lease liabilities, current | 560 |
| Net cash used in operating activities | -140,418 |
| Proceeds from sales and maturities of marketable securities | 283,376 |
| Purchases of marketable securities | 156,575 |
| Net cash provided by investing activities | 126,801 |
| Proceeds from stock option exercises and employee stock purchase plan issuances | 242 |
| Payment of employee tax obligations related to vesting of restricted stock units | 159 |
| Net cash provided by financing activities | 83 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | -13,534 |
Sage Therapeutics, Inc. (SAGE)
Sage Therapeutics, Inc. (SAGE)